IC50: 2.27 and 4.78 μM against L1210 and K562 cell lines

Ligustilide, isolated and purified from the essential oil of A. sinensis. Ligustilide has been reported to facilitate blood circulation and attenuate inflammatory pain behavior.

In vitro: Previous results showed pretreatment with Ligustilide (LIG) improved cell viability significantly. The apoptosis rate in glutamate-induced PC12 cells decreased in the presence of LIG. Western blot results indicated that LIG could decrease the release of Cyt C from mitochondria, up-regulate Bcl-2/Bax ratio and down-regulate Caspase-3 protein expression, resulting in protecting PC12 cells from apoptosis [1].

In vivo: In ovariectomized (OVX) osteopenic rats, the anti-inflammatory potential of LIG was determined by ELISA. LIG was found to be able to inhibit OVX-induced up-regulation of NF-κB activation and the production of TNF-α, iNOS, IL-1β, ICAM-1 and COX-2 significantly. In addition, LIG could suppress MDA and PMN infiltration. The significant anti-inflammatory effect of Ligustilide in experimental OVX osteopenic rats clearly demonstrated that there might be an inflammatory component in the etiology of osteoporosis [2].

Clinical trial: N/A

References:
[1] Wu Q,Wang N,Wang Y,Wang GY,Piao XX.? rotective effect of ligustilide against glutamate-induced apoptosis in PC12 cells. Yao Xue Xue Bao.2015 Feb;50(2):162-8.
[2] Ma Z,Bai L.? The anti-inflammatory effect of Z-Ligustilide in experimental ovariectomized osteopenic rats. Inflammation.2012 Dec;35(6):1793-7.